A placebo-controlled comparison of zotepine versus chlorpromazine in patients with acute exacerbation of schizophrenia

Acta Psychiatrica Scandinavica

Volumn 101, Issue 3, 2000, Pages 218-225

  Cooper, S J ^a   Tweed, J ^b   Raniwalla, J ^b   Butler, A ^b   Welch, C ^b  

^a QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

^b ABBOTT LABORATORIES   (United States)

Author keywords

Chlorpromazine; Negative symptoms; Positive symptoms; Schizophrenia; Zotepine

Indexed keywords

CHLORPROMAZINE; PLACEBO; ZOTEPINE;

ADULT; ARTICLE; ASTHENIA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE EXACERBATION; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; EXTRAPYRAMIDAL SYMPTOM; FEMALE; HUMAN; HUMAN TISSUE; INSOMNIA; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NERVOUSNESS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SCHIZOPHRENIA; SCORING SYSTEM; SOMNOLENCE;

ACUTE DISEASE; ADOLESCENT; ADULT; ANTIPSYCHOTIC AGENTS; CHLORPROMAZINE; DIBENZOTHIEPINS; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DYSKINESIA, DRUG-INDUCED; FEMALE; HUMANS; MALE; MIDDLE AGED; PSYCHIATRIC STATUS RATING SCALES; SCHIZOPHRENIA; TREATMENT OUTCOME;

EID: 0001584620     PISSN: 0001690X     EISSN: None     Source Type: Journal    
DOI: 10.1034/j.1600-0447.2000.101003218.x     Document Type: Article

References (21)

1. 1. Kane J, Honigfeld G, Singer J, Meltzer H. Clozapine for the treatment-resistant schizophrenic: a double-blind comparison with chlorpromazine. Arch Gen Psychiatry 1988; 45:789-796.
2. 2. Borison RL. Clinical efficacy of serotonin dopamine antagonists relative to classic neuroleptics. J Clin Psychopharmacol 1995;15(Suppl. 1):24S-29S.
3. 3. Needham PL, Skill MJ, Heal DJ. Zotepine: preclinical tests predict antipsychotic efficacy and an atypical profile. Psychopharmacol Bull 1996;32:123-128.
4. 4. Roth BL, Craigo SC, Choudhary MS et al. Binding of typical and atypical antipsychotic agents to 5-hydroxytryptamine-6 and 5-hydroxytryptamine-7 receptors. J Pharmacol Exp Ther 1994;268:1403-1409.
5. 2 receptors. Psychopharmacology 1993;112:40-54.
6. 6. Fleischhacker WW, Barnas C, Stuppack CH, Unterweger B, Miller C, Hinterhuber H. Zotepine vs haloperidol in paranoid schizophrenia: a double-blind trial. Psychopharmacol Bull 1989;25:97-100.
7. 7. Petit M, Raniwalla J, Tweed J, Leutenegger E, Dollfus S, Kelly F. A comparison of an atypical and typical antipsychotic, zotepine versus haloperidol in patients with acute exacerbation of schizophrenia. Psychopharmacol Bull 1996; 32:81-87.
8. 8. Müller-Spain F, Dieterle DM, Ackenheil M. Clinical efficacy of zotepine in the treatment of schizophrenic negative symptoms. Fortschr Neurol Psych 1991;59(Suppl. 1): 30 35.
9. 9. Barnas C, Stuppack CH, Miller CH, Haring C, Sperner-Unterweger B, Fleischhacker WW. Zotepine in the treatment of schizophrenic patients with prevailing negative symptoms. A double-blind trial versus haloperidol. Int Clin Psychopharmacol 1992;7:23-27.
10. 10. Johnstone EC, Owens DGC, Crow TJ, Davis JM. Does a four-week delay in the introduction of medication alter the course of a functional psychosis? J Psychopharmacol 1999; 13:238-244.
11. 11. American Psychiatric Association (APA). Diagnostic and statistical manual of mental disorders, 3rd edn, revised (DSM-III-R). Washington DC: APA, 1987.
12. 12. Guy W. ECDEU assessment for psychopharmacology. DHEW Publication 76338. 1976:218-222.
13. 13. Overall JE, Gorham DR. The Brief Psychiatric Rating Scale. Psychol Rep 1962;10:799-812.
14. 14. Andreasen NC. The scale for the assessment of negative symptoms (SANS): conceptual and theoretical foundation. Br J Psychiatry 1989;155(Suppl 7):49-58.
15. 15. US Food and Drug Administration (USFDA), Coding Symbols for Thesaurus of Adverse Reaction Terms. Rockville, MA: USFDA.
16. 16. Simpson GM, Angus JSW. A rating scale for extra-pyramidal side effects. Acta Psychiatr Scand 1970;45 (Suppl. 212):11-19.
17. 17. Guy W. ECDEU assessment for psychopharmacology. DREW Publication 76338 1976;534-537.
18. 18. Tsutani H, Miyamae M, Kagawa D, Uchida M, Domae N, Nakamura T. Uricosuric effect of zotepine and its action mechanism. Uric Acid Res 1985;9:55-60.
19. 19. Data on file. Investigator's brochure. Zotepine. Nottingham, UK: Knoll Pharmaceutical, 1994.
20. 20. Feighner JP, Boyer WF. Selective serotonin re-uptake inhibitors: perspective in psychiatry. In: Boyer WF, Feighner JP ed. Selective reuptake inhibitors. New York, Chichester: John Wiley, 1991:89-132.
21. 21. Small JG, Hirsch SR, Arvanitis LA et al. Quetiapine in patients with schizophrenia. A high-and low-dose double-blind comparison with placebo. Arch Gen Psychiatry 1997; 101:549-557.